Transcatheter Pulmonary Valve Implantation in Carcinoid Heart Disease

Area of Science:

• Cardiology
• Cardiac Surgery
• Interventional Cardiology

Background:

• Carcinoid heart disease (CHD) is a rare condition characterized by fibrosis of the endocardium, primarily affecting the right-sided heart valves, leading to significant tricuspid and pulmonary regurgitation.
• Right-sided heart failure is a common consequence of advanced CHD, necessitating timely intervention.
• Surgical valve replacement is the standard treatment for symptomatic patients or those with right heart remodeling.

Observation:

• This case report details a patient with severe pulmonary valve regurgitation secondary to carcinoid heart disease.
• The pulmonary regurgitation developed 4 years after a previous surgical tricuspid valve replacement.
• The patient presented with symptoms and signs of right heart failure attributable to the severe pulmonary regurgitation.

Findings:

• The patient underwent successful direct transcatheter pulmonary valve implantation (TPVI).
• This procedure was performed without the need for pre-stenting of the pulmonary valve.
• The transcatheter approach provided a minimally invasive solution for severe pulmonary regurgitation in a complex CHD patient.

Implications:

• Direct TPVI is a viable and effective treatment option for severe pulmonary valve regurgitation in carcinoid heart disease, even in the context of prior cardiac surgery.
• This approach may avoid complications associated with pre-stenting, offering a potentially safer alternative.
• Transcatheter therapies are expanding treatment possibilities for rare conditions like carcinoid heart disease, improving patient outcomes.